71,498 Orion Corporation A shares converted into B shares

ORION CORPORATIONSTOCK EXCHANGE RELEASE – OTHER INFORMATION DISCLOSED ACCORDING TO THE RULES OF THE EXCHANGE27 NOVEMBER 2025 at 9.00 EET          71,498 Orion Corporation A shares converted into B shares In accordance with Section 3 of the Articles of Association of Orion Corporation, 71,498 A shares have been converted into 71,498 B shares. The conversion has been entered into the Trade Register on 27 November 2025.The total number of shares in Orion Corporation is 141,134,278...

Espoo, 27/11/2025 (informazione.news - comunicati stampa - salute e benessere)

ORION CORPORATION
STOCK EXCHANGE RELEASE – OTHER INFORMATION DISCLOSED ACCORDING TO THE RULES OF THE EXCHANGE
27 NOVEMBER 2025 at 9.00 EET
        

71,498 Orion Corporation A shares converted into B shares

In accordance with Section 3 of the Articles of Association of Orion Corporation, 71,498 A shares have been converted into 71,498 B shares. The conversion has been entered into the Trade Register on 27 November 2025.

The total number of shares in Orion Corporation is 141,134,278 which, after the conversion, consists of 31,770,319 A shares and 109,363,959 B shares. The number of votes of the company's shares is after the conversion 744,770,339.

Orion Corporation

Liisa Hurme President and CEO

Mikko Kemppainen General Counsel

Contact person:
Tuukka Hirvonen, Head of Investor Relations, tel. +358 10 426 2721
                                                 

Publisher:
Orion Corporation
Communications
Orionintie 1A, FI-02200 Espoo, Finland
http://www.orionpharma.com

Orion is a globally operating Nordic pharmaceutical company – a builder of well-being for over a hundred years. We develop, manufacture and market human and veterinary pharmaceuticals and active pharmaceutical ingredients. Orion has an extensive portfolio of proprietary and generic medicines and consumer health products. The core therapy areas of our pharmaceutical R&D are oncology and pain. Proprietary products developed by Orion are used to treat cancer, neurological diseases and respiratory diseases, among others. In 2024 Orion's net sales amounted to EUR 1,542 million and the company employed about 3,700 professionals worldwide, dedicated to building well-being. Orion's A and B shares are listed on Nasdaq Helsinki.